In 39 hookworm-naive US adults given one of three Na-GST-1 vaccine formulations or placebo before controlled hookworm challenge, infection rates did not differ significantly (CpG formulation 2/5 vs placebo 4/7; 31 analysed). No related serious adverse events.
RCTn = 39
DiRosato et al. Na-GST-1 adsorbed on Alhydrogel co-administered with different Toll-like receptor agonists in hookworm-naive adults using a controlled human infection model in the USA: a phase 2, double-blind, randomised controlled trial